SOPHARMA AD - Notification

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 1 / 2017

Date of issue: 2017-01-06

Short name of the issuer

SOPHARMA AD

Subject

Notification

Official market - legal basis

art. 17. 1 MAR.

Unofficial market - legal basis

Contents of the report:

2017 starts with good news concerning the registration and further development of our product Tabex. The buyer of the share of Sopharma AD in Extab – Achieve – is undertaking a merger with another strong player in the development and registration of innovative medicines – Oncogenex, a publicly traded company on NASDAQ (http://in.reuters.com/article/idINFWN1EV0QP). The procedure is expected to be completed by mid 2017 subject to approval from the US FSC. Sopharma AD will own approximately 3.5% in the newly created company, which will aim at filing the IND for Tabex in 2017. Apart from the work on Tabex, the new company is also active in the development of other medicines, including one to facilitate the process of treating certain types of cancer.

Annexes

File Description

Notification_06.01.17.doc Notification

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2017-01-06 Ognain Donev Executive director